JP Morgan Healthcare Conference January 9, 2007 Larry Best EVP and Chief Financial Officer
|
|
- Angelica Powell
- 6 years ago
- Views:
Transcription
1 Note: During the January 9 th Boston Scientific presentation at the JP Morgan Healthcare Conference, slide 26 incorrectly presented for 2006 the mid-point of our previously announced range of worldwide drug-eluting stent revenue. The estimated mid-point should have been reflected as $2.4 billion as opposed to $2.3 billion. JP Morgan Healthcare Conference January 9, 2007 Larry Best EVP and Chief Financial Officer
2 Cautionary Statement for Purposes of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995 The presentations at this meeting contain forward-looking statements. The Company desires to take advantage of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995 and is including this statement for the express purpose of availing itself of the protections of the safe harbor with respect to all forward-looking statements. Therefore, the Company wishes to caution each participant at this meeting to consider carefully the specific factors discussed with each forward-looking statement in these presentations and other factors contained in the Company s filings with the Securities and Exchange Commission as such factors in some cases have affected, and in the future (together with other factors) could affect, the ability of the Company to implement its business strategy and may cause actual results to differ materially from those contemplated by the statements expressed herein. 2
3 Growth History and Goals ($M) Low Range Estimate $8,647 $7,800 Positioned for Long-Term Growth $6,283 $5,624 $3,476 $1,191 $1,551 $1,831 $2,234 $2,842$2,664 $2,673 $2,919 3 '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06E '07 Low Range Note: As reported actuals through 2005, 2006 as reported estimate, 2007 low range estimate Estimate
4 The New Boston Scientific 2007 Low Range Estimate of $8.6B CRM 23% Neuromodulation 4% two DES platforms DES 26% Endosurgery 17% Other Cardiovascular 30% 4
5 The New Boston Scientific: Achieving Leadership is Our Goal $ 27B Global Market Cardiovascular $ 9B Global Market $ 1.5B Global Market Endosurgery Neuromodulation Interventional Cardiology Cardiac Surgery Endoscopy Pain Management CRM Electrophysiology Oncology Auditory Peripheral Interventions Vascular Surgery Urology Gynecology Neurovascular Positioned for Growth with 3 Operating Groups in 12 Growth Markets Internal Estimates 5
6 Boston Scientific Best Positioned in Cardiovascular Market Changing Competitive Dynamics of a $27B Market IC CRM Boston Scientific 1 2? Medtronic St. Jude Abbott JNJ ? - - Note: BSC-Guidant based on Wall Street Case and Company estimates, reflecting trailing twelve months and full year of combined operation. All others based on Wall Street Research. 6
7 Opportunities for 2007 and beyond
8 Goals for 2007 Satisfy FDA on Quality Accomplish Lifting of FDA Warning Letters Obtain Product Pipeline Approvals Reduce Debt associated with GDT Acquisition Focus on Spending Discipline Strengthen Balance Sheet Prepare for Re-acceleration of Growth 8
9 CRM Market Opportunities
10 WW CRM Market $20 B US Defibrillator market recovery will boost WW market Int l markets are at lower penetrations than US and have attractive long-term growth potential 4% - 8% $ $12.1 $10 B 16% $9.4 - $9.6 $0 B Defibrillator Revenue Range Pacemaker Internal Estimates 10
11 WW Defibrillator Market $20 B Largely under-penetrated markets Clear and compelling clinical science Aligned with practice guidelines Appropriate reimbursement coverage $10 B Expanding number of implanters 7% - 13% $7.0 - $8.4 29% $5.6 - $5.7 $0 B US Revenue Range International Internal Estimates 11
12 CRM Strategy Phased Approach Restore Trust & Confidence Regain Market Position Put in place new leadership team Transparent product performance communications Improve quality and reliability processes Clear the warning letter Commitment to quality and reliability Focus sales force & enhance sales and marketing execution Restore product cadence: LATITUDE VITALITY NXT ACUITY TELIGEN & COGNIS Move Toward Leadership Continue focus on quality and reliability Best-in-class sales and marketing execution Build on Heart Failure advantages Continue tradition of innovation 12
13 CRM Warning Letter Status Clearing the St. Paul site Warning Letter continues to be the top priority of the CRM organization. Completed all 65 commitments that were made to FDA in response to its Warning Letter observations Conducted a broad review of our Quality System (beyond the scope of the FDA s observations) Met with FDA to outline our progress relative to these Quality System improvements 13 Inspections completed in Q4, 2006
14 Restore Product Cadence 1H07 2H Remote Patient Management Heart Failure SCD Prevention LATITUDE expansion emr Integration Cadence of Enhancements ACUITY Steerable ACUITY Spiral ACUITY LDS COGNIS IS-4 Family VITALITY NXT IS-4 Family TELIGEN Note: Anticipated approximate launch timing for US; International timing may differ Not available for sale in the US. CAUTION: Investigational Device. Limited by Federal Law to investigational use. 14
15 LATITUDE Connecting Patients with Caregivers Patient s Home Boston Scientific CRM ICD or CRT-D HF Managing Physician & RN LATITUDE Communicator LATITUDE Web Server Objectives Heart Failure management Compliance with Guidelines emr LATITUDE Weight Scale Device Managing Physician & AHP LATITUDE BP Monitor Objectives Device management Arrhythmia management Note: RENEWAL 3 RF is currently the only device approved for use with the wireless LATITUDE system in the U.S. 15
16 Moving Toward CRM Market Leadership 16
17 Neuromodulation Market Opportunities
18 U.S. Neuromodulation Market ($M) Neuromodulation is a fast growing market with Spinal Cord Stimulation being the largest segment $965 $1,160 $1,430 $1,770 $2,135 $2,500 CAGR 19% 24% Neuromodulation excluding SCS market, but including deep brain stimulators, drug pumps, sacral nerve stimulators, vagus nerve stimulators Spinal Cord Stimulation Market $1B+ SCS market with 20% annual growth 18 Source: Millennium Research Group (July 2006); Bank of America Equity Research (June 2006)
19 U.S. Pain Management Market Share By Last 8 Quarters 6% 24% 12% 24% 13% 27% 14% 26% 18% 24% 21% 24% 23% 23% 24% 23% 70% 64% 60% 60% 58% 55% 54% 53% Q4 04' Q1 05' Q2 05' Q3 05' Q4 05' Q1 06' Q2 06' Q3 06' MDT ANS BSC Source: Based on Analyst Calls and reports with internal analysis; * U.S. IPG sales only; For ANS, No OEM data or international revenue is included 19
20 Auditory Market Opportunity ($M) % organic market growth Divisional growth 20%+ Bilateral adoption accelerates to 26% Bilateral plus expanded indications can exceed 30% $500 $450 $400 $350 $300 $250 $200 $150 $100 $50 $0 CAGR ~ 20% Auditory Growth Potential Organic + Bilateral + Hybrid CAGR ~ 20% - 26% CAGR 11 on ~ 26% - 30% Expanded Indications from Hybrid w/drug & Slim Growth to 30% Significant Bilateral Adoption / Growth to 26% Internal Estimates
21 Refractory Migraine The Next Pain Market? U.S. Refractory Migraine Opportunity ~28 M migraine sufferers (13% US adults) Massive Costs: $3 B Drugs $13 B Employer Burden Refractory Patient Options ~2.8 M patients refractory to existing therapies (10%) 21 Source: American Migraine Study II, 2001 Market Opportunity ~1.9 M severe refractory migraine patients candidates for neuromodulation (66%) Penetration 5% Market size ($) $1 Billion
22 Neuromodulation Sales Growth and Goals ($M) $330 CAGR $232 $115 20% $148 $87 $80 $78 $ % $145 $67 $70 $ E Pain Management Auditory 22
23 DES Market Opportunities
24 Evolution of PCI: The dominant coronary revascularization since Over the last 30 years, percutaneous coronary intervention (PCI) has undergone progressive improvements in success, safety, and durability, as serial new technologies have been launched. While each innovations solved a serious prior problem, it has sometimes introduced rare new adverse events (e.g., in-stent restenosis, stent thrombosis). Event Rate Failure Em CABG Restenosis Stent thrombosis VLST Current results of DES-PCI are the BEST they have ever been 24 0 POBA early POBA late Stent early Stent late DES present Innovations over time
25 DES Market Dynamics
26 DES Market Dynamics (excluding Japan) ($B) $1.6 $3.9 $4.8 $4.8 $0.1 $0.1 $0.1 $0.3 Internal Estimates $1.7 $2.1 $2.1 $1.4 $2.1 $2.6 $2.4 $ E BSC JNJ MDT Other 26 Note: During the January 9 th Boston Scientific presentation at the JP Morgan Healthcare Conference, slide 26 incorrectly presented for 2006 the mid-point of our previously announced range of worldwide drug-eluting stent revenue. The estimated mid-point should have been reflected as $2.4 billion as opposed to $2.3 billion. This slide reflects this correction.
27 TAXUS Program Keys to Success with Changing Market Dynamics Reinforce TAXUS Safety No increase in adverse patient events compared to BMS 50% reduction in patient re-intervention Demonstrate continued TAXUS efficacy Highlight most recent clinical data Reinforce TAXUS deliverability advantage Highlight Express 2 /Cypher and Liberté / ENDEAVOR comparisons Demonstrate the Pipeline Create global enthusiasm around TAXUS Liberté 27
28 TAXUS Liberté Stent Second Generation DES - #1 O.U.S Proven Efficacy* Thinner struts Open cells DES design SV, LV, WH BWR Side Branch Access 2H 2007 Launch-USA *The TAXUS Liberte stent system is not available in the U.S. Caution: Investigational Device. Limited by Federal Law to investigational use 28 Excludes Japan.
29 Japan DES Market and Penetration Size ($M) $700 $600 $500 67% $157 71% $139 72% $136 DES Penetration 80% 70% 60% $400 $300 $200 $278 $456 $512 $548 50% 40% 29 $100 $0 $121 25% 30% 20% E DES Market Size ($M) BMS Market Size ($M) DES Penetration TAXUS Express Launch Expected Q3, 2007 Internal Estimates
30 TAXUS and PROMUS Stents A Powerful Combination TAXUS Paclitaxel-Eluting Coronary Stent System The Best DES Solution Unsurpassed Deliverability Proven Clinical Outcomes PROMUS Everolimus-Eluting Coronary Stent System A Promising DES Solution Promising Clinical Outcomes A Deliverable Olimus The only company offering two DES platforms 30
31 PROMUS Stent Launch Update Private-labeled Xience V Stent Manufactured by Abbott Right to 50% of Abbott capacity CE Marked in October 2006 BSC Launch Timeline: December Limited launch Q1, 07 Expanded launch Q2, 07 Full launch 31
32 DES Pipeline USA Timing Investing for Sustained DES Leadership Planned DES Pipeline Cadence TAXUS Liberté Stent TAXUS Express Expansion TAXUS Express Japan Mid H H 2007 Second generation with improved deliverability 2.25/4.0 sizes First generation TAXUS Liberté Expansion #1 PROMUS Stent 2H H mm & 32mm Most deliverable olimus TAXUS Element Stent 2009 Third generation with improved performance TAXUS Liberté Expansion #2 1H 2009 Large vessel 4.5/5.0 & 38 mm TAXUS² Petal Stent Barrolimus 2010 TBA Bifurcation Element + Everolimus Odyssey TBA Disruptive technology CAUTION: TAXUS Express &4.0mm, TAXUS Liberté and PROMUS are investigational devices. Limited by U.S. Federal law to investigational use. Not for sale. TAXUS Barracuda under development. Not for sale. TAXUS Petal, Barrolimus and Odyssey are under development and not available for sale. 32 Internal Estimates
33 Carotid Market Opportunities
34 Carotid Market Development Market Size (Stent plus Embolic Protection Device) ($M) $1,000 $750 $750 $950 High $1,100 Low $800 $ CAGR: 24-31% $500 $250 $0 $130 $80 $50 $60 $80 $105 $140 $165 $220 Int l US $500 $525 $400 $350 $325 $225 $ U.S. CMS Reimbursement: HR Asx, SX nhr Internal Estimates HR= High Risk; nhr = non High Risk; Asx = Asymptomatic; SX = Symptomatic 34
35 Carotid Solutions - Potential to Leadership System: Now Approved NexStent & FilterWire EZ Carotid WALLSTENT & FilterWire EZ Clinical: US Regulatory Approval Status: Q4/06 Q3/07 EU Performance: Leadership Position 35 Internal Estimates
36 Endosurgery Opportunity
37 Worldwide Endosurgery Sales ($ M) Long-Term Predictable Double-Digit Growth $520 $ % $682 +9% $746 +9% $ % $ % $1,227 $1, % +12% $1, % +13% CAGR E
38 Worldwide Endosurgery Divisional Sales ($M) Long-Term Predictable Double-Digit Growth Oncology Uro & Gyn Endoscopy $520 $102 $132 $286 $ % $108 $144 $373 $682 +9% $115 $156 $411 $746 +9% $127 $169 $451 $ % $142 $196 $514 $ % $166 $226 $580 $1, % $1, % $186 $261 $641 $207 $324 $697 $1, % $221 $371 $ % CAGR E
39 Endosurgery Group Core Products and Pipeline Priorities Businesses Core Franchises Key New Products Pipeline Priorities (2011 Market Potential) Urology & Gynecology: Stone Management BPH Pelvic Floor Single-Incision Sling Slings & Pelvic Floor Reconstruction NG HTA AUB Endoscopy: Biliary Stents Hemostasis Biopsy & Polypectomy RJ4 Spy Resolution II Wallflex Biliary Benign indication expansion Procedural expansion into the Biliary System Endoscopic Ultrasound (EUS) Dilatation Wallflex Enteral Enteral Feeding Oncology: Venous Access-PASV RF Ablation Peripheral Embolization Drainage & Biopsy PASV Power PICC Interlock Detachable Coil Surgical Resection RF Market Expansion Implantable Venous Access Ports Bioactive Coatings Broad Base Launches Long-Term Growth 39
40 Boston Scientific has never been better positioned for long-term growth
41 The New Boston Scientific 2007 Low Range Estimate of $8.6B CRM 23% Neuromodulation 4% two DES platforms DES 26% Endosurgery 17% Other Cardiovascular 30% 41
42 Growth History and Goals ($M) Low Range Estimate $8,647 $7,800 Positioned for Long-Term Growth $6,283 $5,624 $3,476 $1,191 $1,551 $1,831 $2,234 $2,842$2,664 $2,673 $2, '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06E '07 Low Range Note: As reported actuals through 2005, 2006 as reported estimate, 2007 low range estimate Estimate
43 Execution... People, Technology, Opportunity 43
44 JP Morgan Healthcare Conference January 9, 2007 Larry Best EVP and Chief Financial Officer
Abbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE. January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO
Abbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO FORWARD LOOKING STATEMENT Some statements in this presentation may be forward-looking
More informationSales by Geographic Segment. Sales by Product Category
2008 Annual Report n3 Transformed quality n3 Revitalized the pipeline n3 Streamlined the organization n3 Strengthened financial fundamentals n3 Diversified product portfolio Driving Success 2008 Sales
More informationBoston Scientific - Company Profile
Contents Boston Scientific - Company Profile 1 Boston Scientific 1.1 Company Overview 1.1.1 Key Facts 1.1.1.1 Primary business divisions 1.1.1.2 Key products 1.1.1.3 Significant subsidiaries 1.1.2 Key
More informationPrecision Vascular Robotics. Corindus Vascular Robotics (CVRS) January 2017
Precision Vascular Robotics Corindus Vascular Robotics (CVRS) January 2017 1 Forward Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS (AS SUCH TERM IS DEFINED IN SECTION 27A OF
More informationTransforming Surgical Robotics. 34 th Annual J.P. Morgan Healthcare Conference January 14, 2016
1 Transforming Surgical Robotics 34 th Annual J.P. Morgan Healthcare Conference January 14, 2016 Forward Looking Statements 2 This presentation includes statements relating to TransEnterix s current regulatory
More informationMedtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results. May 24, :45 AM CT. Medtronic plc
Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results May 24, 2018 5:45 AM CT Medtronic plc Q4 Revenue of $8.1 Billion Grew 2.9% Reported and 6.5% Organic Q4 GAAP Diluted EPS of $1.07;
More informationMEDTRONIC. That s a lot of Solid Heart Beats. INVESTMENT THESIS FINANCIAL STATISTICS COMPANY PROFILE. Financial History EQUITY RESEARCH
SMUSM COX SCHOOL OF BUSINESS EQUITY RESEARCH UNITED STATES OF AMERICA MEDTRONIC COMPANY UPDATE: Prospects for 2004 HEALTHCARE - Medical Equipment & Supplies PAGE 1 BUY Benjamin Q. Luong Email: luong_benji@hotmail.com
More informationDecember Eucomed HTA Position Paper UK support from ABHI
December 2008 Eucomed HTA Position Paper UK support from ABHI The Eucomed position paper on Health Technology Assessment presents the views of the Medical Devices Industry of the challenges of performing
More informationForward Looking Statements
NYSE MKT: NSPR October 2015 Forward Looking Statements This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects,"
More informationtowerswatson.com Transforming Life Medtronic aligns global total rewards with EVP
towerswatson.com Transforming Life Medtronic aligns global total rewards with EVP Transforming Life Medtronic aligns global total rewards with EVP By Lucie P. Lawrence In 1949, in a 600-square-foot garage
More informationMedtronic plc Revenue Reporting Changes and Combined Historical Revenue, Condensed Statement of Earnings, and Non-GAAP Reconciliations February 17,
Medtronic plc Revenue Reporting Changes and Combined Historical Revenue, Condensed Statement of Earnings, and Non-GAAP Reconciliations February 17, 2015 Updated to Include Combined Q3 FY15 Results 1 TABLE
More informationMedtronic Company Overview
Medtronic Company Overview Creating Meaningful Change Together Together, Medtronic and Covidien are working to improve healthcare by addressing the needs of more people, in more ways, and in more places
More informationBIOTRONIK // Celebrating 50 years of excellence BIOTRONIK. Setting the pace, pioneering the future
BIOTRONIK // Celebrating 50 years of excellence BIOTRONIK Setting the pace, pioneering the future Content 01 Company 02 Corporate history 03 Milestones 04 Innovations 05 Partnerships and training programs
More informationGlobal Transcatheter Aortic Valve Replacement (TAVR) Market: Trends & Opportunities [ ]
Global Transcatheter Aortic Valve Replacement (TAVR) Market: Trends & Opportunities [2013-18] Scope of the Report The report titled Transcatheter Aortic Valve Replacement Market (TAVR): Trends and Opportunities
More informationAcquisition of MST Medical Surgery Technologies Ltd:
Acquisition of MST Medical Surgery Technologies Ltd: Meaningfully Bolsters Senhance Platform Innovation to Further Advance Digital Laparoscopy September 24, 2018 2 FORWARD LOOKING STATEMENTS This presentation
More informationHTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:
HTA Position Paper The Global Medical Technology Alliance (GMTA) represents medical technology associations whose members supply over 85 percent of the medical devices and diagnostics purchased annually
More informationAt a Glance. 8.3 billion 21, % %
Company Overview At a Glance Our Mission We make a difference by caring for the caregivers, helping them maintain order in their organizations and restore health to their patients. fortune 500 company
More informationImplantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast,
Transparency Market Research Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 2018 Buy Now Request Sample Published Date: Mar 2013 Single User
More informationDownhole Monitoring Solutions. Medical Instrumentation
Downhole Monitoring Solutions 1 Medical Instrumentation Forward Looking Statements This corporate presentation contains forward-looking statements, which reflect the Company s current expectations regarding
More informationWelcome Shareholders Annual Meeting. FY2014 March 1, 2013 February 28, 2014
Welcome Shareholders 2014 Annual Meeting March 1, 2013 February 28, 2014 1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of safe-harbor provisions of the
More informationFORM 8-K. MEDTRONIC INC - mdt. Filed: November 20, 2006 (period: November 20, 2006) Report of unscheduled material events or corporate changes.
FORM 8-K MEDTRONIC INC - mdt Filed: November 20, 2006 (period: November 20, 2006) Report of unscheduled material events or corporate changes. Table of Contents 8-K - CURRENT REPORT Item 2.02. Results of
More information1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Global Neurostimulation Devices Market - An Overview 3.
1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Global Neurostimulation Devices Market - An Overview 3.1 Spinal Cord Stimulator 3.2 Deep Brain Stimulator 3.3 Vagus Nerve Stimulator
More informationGabelli & Company, Inc.
One Corporate Center Rye, NY 10580-1422 Tel. (914) 921-8436 Fax (914) 921-5098 www.gabelli.com Gabelli & Company, Inc. Investment Summary Kensey Nash Corp. (KNSY), headquartered in Exton, PA, is a developer
More informationMRI with the VNS Therapy System October 2017
MRI with the VNS Therapy System October 2017 The information contained in this document is one part of the full labeling for the implanted portions of the VNS Therapy System. It is not intended to serve
More informationApril By Type of Approach- Transfemoral and Transapical. By Region- North America, Europe, APAC and RoW
Global Transcatheter Aortic Valve Replacement (TAVR) Market: Analysis By Type of Approach (Transfemoral and Transapical), By Region, By Country: Opportunities and Forecast (2017-2022) By Type of Approach-
More informationJ.P. Morgan Healthcare Conference Summary Transcript
J.P. Morgan Healthcare Conference Summary Transcript Good afternoon, everyone. I'm Shigeo Taniuchi. I'm President and COO of Santen Pharmaceutical. I joined Santen in 1996, and I became the President and
More informationAn Uneasy Marriage: Health Care Technology and its Relationship to Quality
An Uneasy Marriage: Health Care Technology and its Relationship to Quality Richard Afable, MD Orange County Employee Benefits Council January 11, 2007 Agenda Definition of Quality Health Care Discussion
More informationGiuseppe Savoja Curriculum Vitae mob.: Past
International Marketing Manager at Medtronic Geneva Area, Switzerland, Medical Devices Past Marketing Program Manager International Surgical Ablation & Beating Heart Revascularization at Medtronic Product
More informationALANCO TECHNOLOGIES INC
SECURITIES & EXCHANGE COMMISSION EDGAR FILING ALANCO TECHNOLOGIES INC Form: 8-K Date Filed: 2016-10-04 Corporate Issuer CIK: 98618 Copyright 2016, Issuer Direct Corporation. All Right Reserved. Distribution
More informationOrdinary and Extraordinary General Meeting. Brussels, May 24, 2012
Ordinary and Extraordinary General Meeting Brussels, May 24, 2012 1 Results and accomplishments 2011 Count Georges Jacobs de Hagen Chairman of the Board of Directors of Delhaize Group 2 Tough economic
More informationROLL CALL PURCHASE RECOMMENDATIONS
13 Board Meeting September 7, 2017 ROLL CALL PURCHASE RECOMMENDATIONS The "Purchase Recommendations" are presented by campus and a Summary from "Appropriated Funds" (i.e., from State appropriations to
More informationGoldman Sachs Medtech Conference, 9 September Dave Illingworth CEO
Goldman Sachs Medtech Conference, 9 September Dave Illingworth CEO 0 Forward looking statements This presentation contains certain "forward-looking statements" within the meaning of the US Private Securities
More informationULP Wireless Technology for Biosensors and Energy Harvesting
Power Matters ULP Wireless Technology for Biosensors and Energy Harvesting Reghu Rajan September, 2012 Presentation Overview Overview of wireless telemetry and sensors in healthcare Radio requirements
More informationModel Based Design Of Medical Devices
Model Based Design Of Medical Devices A Tata Elxsi Perspective Tata Elxsi s Solutions - Medical Electronics Abstract Modeling and Simulation (M&S) is an important tool that may be employed in the end-to-end
More informationMinimally Invasive Therapies Group
Minimally Invasive Therapies Group Usage Guidelines Updated March 30, 2015 Our Narrative and Businesses We aspire to enable earlier diagnosis, better treatment, faster complication-free recovery and enhanced
More informationSTUART B MITCHELL FOUNDER AND CEO NOVUSON SURGICAL, INC. JUNE 2018
STUART B MITCHELL FOUNDER AND CEO NOVUSON SURGICAL, INC. JUNE 2018 2 Market dominated by 1990 s technology Enseal - 1991-1991 Ethicon (J&J) - 1993-1960 LigaSure - 1992 Covidien (Medtronic) - 1891 HarmonicAce
More informationBOVIE MEDICAL CORPORATION
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationQ2 Fiscal 2018 Earnings Conference Call
Q2 Fiscal 2018 Earnings Conference Call Thursday, February 8, 2018, 4:30 PM Eastern CORPORATE PARTICIPANTS - Chairman, Chief Executive Officer Bill Cavanagh - Chief Operating Officer, Chief Scientific
More informationGuidelines to Promote National Integrated Circuit Industry Development : Unofficial Translation
Guidelines to Promote National Integrated Circuit Industry Development : Unofficial Translation Ministry of Industry and Information Technology National Development and Reform Commission Ministry of Finance
More informationinemi Statement of Work (SOW) Medical TIG Qualification Methods for Portable Medical Products
inemi Statement of Work (SOW) Medical TIG Qualification Methods for Portable Medical Products Version 2.2 Date: December 16, 2011 Project Leader: Grady White, NIST Project Co-leader: Jack Zhu, Boston Scientific
More informationCHINA MED DEVICE. China Medtech Will Continue Its Double Digit Growth in Years to Come
China Medtech Will Continue Its Double Digit Growth in Years to Come The high level characteristics of medtech in China is focused here. Each of the 6 specific sectors according to SWS recommendation will
More informationIntroducing the LumiCoil Platinum Fiducial Marker. Features of LumiCoil Platinum Fiducial Markers. Expanding Innovation in EUS
LumiCoil Platinum Introducing the LumiCoil Platinum Features of LumiCoil Platinum s Expanding Innovation in EUS Ordering Information and Additional Resources LumiCoil Platinum Introducing the LumiCoil
More informationElectronic Material Systems
Electronic Material Systems Barry Russell Operating Vice President 1 Safe Harbor Statement Today s presentations may contain forward-looking statements within the meaning of the Private Securities Litigation
More informationEarly HTA to inform value driven market access and reimbursement planning
Early HTA to inform value driven market access and reimbursement planning Lotte MG Steuten, PhD Associate Prof. Health Technology & Services Research Program Director Health Sciences University of Twente,
More informationFinancing Growth Ventures to Minimize Equity Dilution
Financing Growth Ventures to Minimize Equity Dilution An entrepreneurial team s mission is to develop and grow its venture and to optimize the management team s equity ownership stake. Significant growth
More informationMaking a healthier world
Medical Components With 200 years of expertise in platinum group metals, Johnson Matthey offers medical device manufacturers the security of supply to source, manage, fabricate, and recycle materials for
More informationFax Japan São Paulo (SP) Tokyo Minato-ku , Minami-Aoyama. St. Jude Medical Brasil Ltda.
Atrial Fibrillation Cardiac Rhythm Management Cardiovascular Neuromodulation Global Headquarters One St. Jude Medical Drive St. Paul, Minnesota 55117 USA +1 651 756 2000 +1 651 756 3301 Fax St. Jude Medical
More informationThird Quarter CY 2010 Results. November 04, 2010
Third Quarter CY 2010 Results November 04, 2010 Safe Harbor Disclosure The statements contained in this presentation that are not historical facts are forward-looking statements. The company generally
More informationA Closer Look. LATITUDE NXT Alerts SUMMARY. Alerts. Red Alerts
A Closer Look SUMMARY Boston Scientific s LATITUDE NXT Patient Management System enables a clinician to periodically monitor patient and device information remotely via a Communicator placed in the patient
More informationThe Evolving Eco-system of the Medical Device Industry. An analysis prepared by MassDevice.com
The Evolving Eco-system of the Medical Device Industry An analysis prepared by MassDevice.com Massachusetts Medical Devices Journal LLC, 2008 Who we are MassDevice.com Online business journal covering
More informationNational Medical Device Evaluation System: CDRH s Vision, Challenges, and Needs
National Medical Device Evaluation System: CDRH s Vision, Challenges, and Needs Jeff Shuren Director, CDRH Food and Drug Administration Center for Devices and Radiological Health 1 We face a critical public
More informationMike Hess Vice President, Innovation Medtronic Inc
Mike Hess Vice President, Innovation Medtronic Inc Medtronic Today World headquarters Minneapolis European headquarters Lausanne Asia/Pacific headquarters Singapore $40-60 Billion market capitalization
More informationDriving profitable growth in Greater China. Andy Ho Chief Market Leader Greater China
Driving profitable growth in Greater China Andy Ho Chief Market Leader Greater China Key takeaways China HealthTech market is the 2 nd largest globally and exhibits continued robust growth with significant
More informationTransition PPT Template. J.P. Morgan. June 2015 V 3.0. Energy Equity Conference June 27, 2017
Transition PPT Template J.P. Morgan June 2015 V 3.0 Energy Equity Conference 2017 June 27, 2017 Forward-Looking Statements This presentation contains forward-looking statements, including, in particular,
More informationFMC Technologies Overview Fourth Quarter Director, Investor Relations Matt Seinsheimer
FMC Overview Fourth Quarter 2016 Director, Investor Relations Matt Seinsheimer +1 281.260.3665 matthew.seinsheimer@fmcti.com This presentation contains forward-looking statements intended to qualify for
More informationAdvancing Health and Prosperity. A Brief to the Advisory Panel on Healthcare Innovation
Advancing Health and Prosperity A Brief to the Advisory Panel on Healthcare Innovation November 2014 About ITAC ITAC is the voice of the Canadian information and communications technologies (ICT) industry
More informationSecond Quarter CY 2012 Results. August 2, 2012
Second Quarter CY 2012 Results August 2, 2012 1 Safe Harbor Disclosure Please review our SEC filings on Form 10-K and Form 10-Q The statements contained in this presentation that are not historical facts
More informationSTEVEN W. ORLOW, MD, MMI, FACP, FACC
STEVEN W. ORLOW, MD, MMI, FACP, FACC Professional Summary I am a licensed physician executive with a master's degree followed by board certification in medical informatics and 7 years of Chief Medical
More informationGlobal Robotic Surgery Market: Industry Analysis & Outlook ( )
Industry Research by Koncept Analytics Global Robotic Surgery Market: Industry Analysis & Outlook ----------------------------------------- (2017-2021) June 2017 1 Executive Summary Medical robotics is
More informationMedtronic Payer Solutions
Medtronic Payer Solutions Delivering Cost-Savings Opportunities through Minimally Invasive Surgery In today s business environment, managing employee overhead and healthcare benefit costs necessitate that
More informationCentre for the Advancement of Health Innovations (CAHI)
Centre for the Advancement of Health Innovations (CAHI) Excellence in Clinical Innovation and Technology Evaluation Monday, April 16 th, 2012 The Old Mill Inn and Spa, Toronto ON Leslie Levin MB, MD, FRCP
More informationNavigating the Healthcare Innovation Cycle
Navigating the Healthcare Innovation Cycle Introduction: CIMIT s 20 + years of experience in facilitating more than 600 projects is that innovation in Healthcare is a learnable, teachable process, which
More informationInvestor Relations Presentation April 30, 2013
Investor Relations Presentation April 30, 2013 FORWARD LOOKING STATEMENTS In addition to the historical data contained herein, this document may include forward-looking statements regarding the future
More informationA Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data
External Review of Pan-Canadian Health Organizations Thank you for the opportunity to provide input for your ongoing review of the Pan- Canadian Health Organizations (PCHOs). This submission is made on
More informationAnalysts Ideas of the Week CardioComm Solutions - ECG Software Management
Week of August 29, 2016 Analysts Ideas of the Week CardioComm Solutions - ECG Software Management www.researchfrc.com Sid Rajeev, B.Tech, MBA, CFA Head of Research CardioComm Solutions - ECG Software Management
More informationThe evolution of Medical implant telemetry and Body Area Network
1st Invitational Workshop on Body Area Network Technology and Applications Future Directions, Technologies, Standards and Applications June 19-20, 2011 Worcester Polytechnic Institute The evolution of
More informationFSIC FRANCHISE. Frequently asked questions
Frequently asked questions FSIC FRANCHISE 1. What are the details of the announced transaction? FS Investments ( FS ) and KKR Credit ( KKR ) announced an agreement to form a partnership to provide investment
More informationMidwestern Conference on Optimizing Electrophysiology Patient Care and Procedural
Midwestern Conference on Optimizing Electrophysiology Patient Care and Procedural Success in the EP Lab COMMERCIAL SUPPORT This continuing medical education activity is supported in part with educational
More informationFDA Centers of Excellence in Regulatory and Information Sciences
FDA Centers of Excellence in Regulatory and Information Sciences February 26, 2010 Dale Nordenberg, MD novasano HEALTH AND SCIEN Discussion Topics Drivers for evolution in regulatory science Trends in
More informationSidoti & Company Spring 2017 Convention
Sidoti & Company Spring 2017 Convention March 29, 2017 Jim McCarley Chief Executive Officer Brian Smith CFO & Treasurer Asia The Americas Europe 1 2017 ExOne Safe Harbor Statement These slides may contain
More informationCompact design. Clinical versatility.
GE Healthcare Compact design. Clinical versatility. OEC Fluorostar * 7900 Digital Mobile C-arm Compact system with a small footprint. Platform modularity. Point and shoot usage. Vascular capabilities.
More informationDevice M&A Rebound Continues: With Ardian, Sadra Deals Show Appetite For Big, Early-Stage Acquisitions
Page 1 of 6 RELATED ARTICLES FDC-Windhover Device M&A Rebound Continues: With Ardian, Sadra Deals Show Appetite For Big, Early-Stage Acquisitions By David Cassak, Tom Salemi, In Vivo 12/01/2010 Around
More informationA Strategic Audit of Medtronic PLC
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Honors Theses, University of Nebraska-Lincoln Honors Program Spring 2018 A Strategic Audit of Medtronic PLC Jozzy Carter
More informationHalliburton and Baker Hughes Creating the leading oilfield services company
Halliburton and Baker Hughes Creating the leading oilfield services company Halliburton Investor Relations Contacts: Kelly Youngblood, Vice President Scott Danby, Manager 281.871.2688 or investors@halliburton.com
More informationGenerex Announces Appointment of Executive Management Team
Generex Announces Appointment of Executive Management Team Company Integrates Latest Acquisition and Builds Corporate Foundation for Growth MIRAMAR, FL, November 15, 2018 -- Generex Biotechnology Corporation
More informationBrief to the. Senate Standing Committee on Social Affairs, Science and Technology. Dr. Eliot A. Phillipson President and CEO
Brief to the Senate Standing Committee on Social Affairs, Science and Technology Dr. Eliot A. Phillipson President and CEO June 14, 2010 Table of Contents Role of the Canada Foundation for Innovation (CFI)...1
More informationView wireless version here:
Page 1 of 5 Julie Horst From: AdvaMed SmartBrief [advamed@smartbrief.com] Sent: Wednesday, July 22, 2009 12:42 PM To: Sherrie Conroy Subject: July 22, 2009 - Boston Scientific: Study to boost implantable
More informationSpectra WaveWriter System Implantable Pulse Generator
Spectra WaveWriter System Implantable Pulse Generator Directions for Use CAUTION: Federal law restricts this device to sale, distribution and use by or on the order of a physician. 91171765-02 Content
More informationCOM C. Rozwell
C. Rozwell Research Note 6 October 2003 Commentary Technologies That Ease Pharmaceutical Industry Disruption Several disruptive forces are altering the life science business model. Enterprises must select
More informationCASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within
More informationJefferies 2014 Global Energy Conference. Maryann Seaman Executive Vice President and Chief Financial Officer
Jefferies 14 Global Energy Conference Maryann Seaman Executive Vice President and Chief Financial Officer This presentation contains forward-looking statements intended to qualify for the safe harbors
More informationBayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division
Bayer Inc. Science for a Better Life Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Please review your career path to date, leading to your
More informationMedical Device Practice
Medical Device Practice Fish & Richardson s Medical Device Practice Many of the world s most successful medical device manufacturers, investors, and inventors have one thing in common: they achieve success
More informationConvergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA
EUnetHTA European network for Health Technology Assessment Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA University of Tokyo, October 24,
More informationSecond Quarter 2013 Results August 1, 2013
Second Quarter 203 Results August, 203 2 Safe Harbor Disclosure Please review our SEC filings on Form 0-K and Form 0-Q The statements contained in this presentation that are not historical facts are forward-looking
More informationSurgical Sutures Market By Product Type [Automated Suturing Devices (Disposable Automated Suturing Devices, And Re-Usable Automated Suturing
Surgical Sutures Market By Product Type [Automated Suturing Devices (Disposable Automated Suturing Devices, And Re-Usable Automated Suturing Devices), and Sutures (Sutures by Type (Absorbable & Non-Absorbable),
More informationLeading the Way in Guide Wire Technology
1/13 Leading the Way in Comprehensive portfolio of guide wires Advanced Technology Abbott Vascular Guide Wires / Indications: This HI-TORQUE Guide Wire is intended to facilitate the placement of balloon
More informationContacts: MEDTRONIC ANNOUNCES 2011 GLOBAL HEROES. Distance Runners from Around the World Who Benefit from Medical Technology
NEWS RELEASE Contacts: Rich Fischer Medtronic Foundation 763 505 2975 Ginny Cassidy Medtronic Foundation 763 505 2998 FOR IMMEDIATE RELEASE MEDTRONIC ANNOUNCES 2011 GLOBAL HEROES Distance Runners from
More informationForward Looking Statements
NYSE MKT: NSPR February 2015 Forward Looking Statements This presenta-on contains forward- looking statements. Such statements may be preceded by the words intends, may, will, plans, expects, an-cipates,
More informationEXECUTIVE SUMMARY RESEARCH INTELLIGENCE DRIVING HEALTH SYSTEM TRANSFORMATION IN CANADA
Pan-Canadian Vision and Strategy for Health Services and Policy Research 2014 2019 EXECUTIVE SUMMARY RESEARCH INTELLIGENCE DRIVING HEALTH SYSTEM TRANSFORMATION IN CANADA Partners involved Alberta Cancer
More information2018 Investor Conference. December 5, 2018 Irvine, CA
2018 Investor Conference December 5, 2018 Irvine, CA 2018 Investor Conference David K. Erickson Vice President, Investor Relations Cautionary Statement Presentations and comments made today by the management
More informationSEMICONDUCTOR INDUSTRY ASSOCIATION FACTBOOK
Factbook 2014 SEMICONDUCTOR INDUSTRY ASSOCIATION FACTBOOK INTRODUCTION The data included in the 2014 SIA Factbook helps demonstrate the strength and promise of the U.S. semiconductor industry and why it
More informationDigitalization and TITLE OF. Devices May 2018 PRESENTATION
Digitalization and Globalization TITLE OF of Medical Devices May 2018 PRESENTATION R&D Spend (in Bn) Consolidated ER&D Spending : E-R&D spend is highly consolidated among top 5 OEMs; Imaging and Non-imaging
More informationInnovation and the Changing Practice of Medicine
Innovation and the Changing Practice of Medicine Japan Medical Innovation Symposium David Epstein, Division Head Novartis Pharmaceuticals Tokyo, August 18, 2015 Agenda The Case for Innovation How Novartis
More informationThe Worldwide OEM Electronics Manufacturing Market
The Worldwide OEM Electronics Manufacturing Market Presented by Randall Sherman NEW VENTURE RESEARCH CORPORATION A Technology Market Research Company Nevada City, California Who is New Venture Research?
More informationThird Quarter 2014 Results
Third Quarter 204 Results November 4, 204 Safe Harbor Disclosure Please review our SEC filings on Form 0-K and Form 0-Q The statements contained in this presentation that are not historical facts are forward-looking
More informationNews Release. 3D Systems Corporation 333 Three D Systems Circle Rock Hill, SC NYSE: DDD
News Release 3D Systems Corporation 333 Three D Systems Circle Rock Hill, SC 29730 www.3dsystems.com NYSE: DDD Investor Contact: Stacey Witten Media Contact: Alyssa Reichental Email: Stacey.Witten@3dsystems.com
More informationCongenital Heart Surgery with a Silicon Valley Perspective
Congenital Heart Surgery with a Silicon Valley Perspective I was fishing yesterday, and George called to see if my slides were ready for my talk today Redmond P. Burke MD Chief, Division of Cardiovascular
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationIndustry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization
Accenture Life Sciences Rethink Reshape Restructure for better patient outcomes Industry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization Accenture Research Note: Key findings
More information